SMTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sanara Medtech Inc (SMTI) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. The technical indicators are neutral to bearish, there are no strong trading signals, and while the company is showing growth in revenue, its negative earnings and lack of significant catalysts make it less attractive for immediate investment.
The MACD is below zero and negatively contracting, indicating bearish momentum. The RSI is neutral at 44.818, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot point of 18.305, with key resistance at 19.945 and support at 16.664.
The company achieved record annual revenue of $103.1 million in 2025, reflecting a 19% YoY increase. FY 2026 revenue projections indicate continued growth of 13%-17%. Gross margin increased to 90.77%, up 4.02% YoY.
The company reported a Q4 GAAP EPS of -$0.19, and net income remains negative at -$1.61 million. Technical indicators are bearish, and there is no significant hedge fund, insider, or congress trading activity to suggest strong sentiment.
In Q4 2025, revenue increased by 4.72% YoY to $27.5 million, and gross margin improved to 90.77%. However, net income remains negative at -$1.61 million, and EPS is -$0.19, despite a 5.56% YoY improvement.
No analyst rating or price target data available for SMTI at this time.
